Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic disruption of interferon-gamma signalling, includin...
Guardado en:
Autores principales: | Enrique J. Arenas, Alex Martínez-Sabadell, Irene Rius Ruiz, Macarena Román Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquín Arribas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aa94e03a034246f68048ebc589ddfa65 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
por: Zhifen Yang, et al.
Publicado: (2021) -
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Charlotte E. J. Downes, et al.
Publicado: (2021) -
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Barbara Savoldo, et al.
Publicado: (2021) -
Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19
por: Tianchuan Zhu, et al.
Publicado: (2021) -
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Congcong Zhang, et al.
Publicado: (2021)